Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 425-432 , May 2007

Cellular metabolic responses of PET radiotracers to 188Re radiation in an MCF7 cell line containing dominant-negative mutant p53

  • Gi Jeong Cheon

      Affiliations

    • Laboratory of Nuclear Medicine Research, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Nowon-Gu, Seoul 139-706, South Korea. Tel.: +82 2 970 1341; fax: +82 2 970 1341.
    • ,
  • Hye-Kyung Chung

      Affiliations

    • Laboratory of Nuclear Medicine Research, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • ,
  • Jung-A Choi

      Affiliations

    • Laboratory of Radiation Experimental Therapeutics, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • ,
  • Su-Jae Lee

      Affiliations

    • Laboratory of Radiation Experimental Therapeutics, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • ,
  • Soon-Hyuk Ahn

      Affiliations

    • Laboratory of Nuclear Medicine Research, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • ,
  • Tae-Sup Lee

      Affiliations

    • Laboratory of Nuclear Medicine Research, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • ,
  • Chang Woon Choi

      Affiliations

    • Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea
    • ,
  • Sang Moo Lim

      Affiliations

    • Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, South Korea

Received 14 September 2006 ,Revised 28 January 2007 ,Accepted 29 January 2007.

References 

  1. Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, et al. Association wit Cdc-2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene. 1999;18:2892–2900
  2. Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin KH, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799–1805
  3. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995;55:1649–1654
  4. Murphy KL, Dennis AP, Rosen JM. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 2000;14:2291–2302
  5. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol. 2004;53:519–524
  6. Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 2001;277:15–30
  7. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331
  8. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117–129
  9. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol. 2001;3:E277–E286
  10. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112–126
  11. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest. 2002;110:3–8
  12. Hsieh BT, Callahan AP, Beets AL, Ting G, Knapp FF. Ascorbic acid/saline eluent increases 188Re yields after wet storage of W/Re generators. Appl Radiat Isot. 1996;47:23–26
  13. Chen FD, Hsieh BT, Wang HE, Ou YH, Yang WK, Whang-Peng J, et al. Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals. Nucl Med Biol. 2001;28:835–844
  14. Warburg O, Wind F, Negalein E. The metabolism of tumours in the body. J Physiol. 1927;8:519–530
  15. Pauwels EKJ, Ribeiro MJ, Stoot JHMB, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317–322
  16. Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of o-(2-[18F]Fluoroethyl)-l-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367–1373
  17. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912–915
  18. Lim SJ, Kim EH, Woo KS, Chung WS, Choi CW, Lim SM. Induction of G2 arrest and apoptosis of Raji cells by continuous low-dose beta irradiation with 188Re-perrhenate. Cancer Biother Radiopharm. 2006;21:314–320
  19. Knapp FF, Callahan AP, Beets AL, Mirzadeh S, Hsieh BT. Processing of reactor-produced tungsten-188 for fabrication of clinical scale alumina-based tungsten-188/rhenium-188 generator. Appl Radiat Isot. 1994;45:1123–1128
  20. Hsieh BT, Liu CJ, Hsieh HS, Tsai ET, Ting G, Knapp FF. The preparation of W-188/Re-188 generator for therapeutic and diagnostic applications. Nucl Sci J. 1996;23:26–38
  21. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. J Biol Chem. 1997;272:22776–22780
  22. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–387
  23. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot sports in p53. Science. 1996;274:430–432
  24. Glebov OK, McKenzie KE, White CA, Sukumar S. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res. 1994;54:3703–3709
  25. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221
  26. Bohnke A, Westphal F, Schmidt A, EL-Awady RA, Dahm-Daphi J. Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells. Int J Radiat Biol. 2004;80:53–63
  27. Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y. Inactivation of p53 increase the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res. 1997;3:1653–1660
  28. Hara S, Nakashima S, Kiyono T, Sawada M, Yoshimura S, Lwama T, et al. Ceramide triggers caspase activation during gamma-radiation-induced apoptosis of human glioma cells lacking functional p53. Oncol Rep. 2004;12:119–123
  29. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–1217
  30. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1134–1136

☆ This study was partly supported by Korea Science and Engineering Foundation and Ministry of Science & Technology, Republic of Korea, through its National Nuclear Technology Program.

PII: S0969-8051(07)00037-6

doi: 10.1016/j.nucmedbio.2007.01.011

Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 425-432 , May 2007

Article Tools

* Image Usage & Resolution